Skip to content
Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article BREAKING: FDA Rejects Lykos Therapeutics’ MDMA-Assisted Therapy For PTSD

BREAKING: FDA Rejects Lykos Therapeutics’ MDMA-Assisted Therapy For PTSD

  • Post published:August 9, 2024
  • Post category:Analysis/News
Read more about the article Vibe Check: FDA Set to Decide Future of MDMA-Assisted Therapy This Week

Vibe Check: FDA Set to Decide Future of MDMA-Assisted Therapy This Week

  • Post published:August 6, 2024
  • Post category:Analysis/News
Read more about the article Psychedelic Funding Update: Q2 2024

Psychedelic Funding Update: Q2 2024

  • Post published:August 1, 2024
  • Post category:Analysis/Pα+
Read more about the article Regulation Beyond Prohibition: RAND Corporation Delivers Report on US Psychedelic Policymaking

Regulation Beyond Prohibition: RAND Corporation Delivers Report on US Psychedelic Policymaking

  • Post published:July 16, 2024
  • Post category:Analysis/News/Pα+
Read more about the article Dutch Committee Seeks to Expedite MDMA-Assisted Therapy for PTSD

Dutch Committee Seeks to Expedite MDMA-Assisted Therapy for PTSD

  • Post published:July 9, 2024
  • Post category:Analysis/News/Pα+
Read more about the article In Brief: ICER Issues Final Evidence Report and Recommendations Re: MDMA-Assisted Therapy; Lykos Responds

In Brief: ICER Issues Final Evidence Report and Recommendations Re: MDMA-Assisted Therapy; Lykos Responds

  • Post published:June 27, 2024
  • Post category:Analysis/News
Read more about the article No NHS Coverage for Janssen’s Spravato: NICE Denies Re-Appraisal of Esketamine for TRD

No NHS Coverage for Janssen’s Spravato: NICE Denies Re-Appraisal of Esketamine for TRD

  • Post published:June 21, 2024
  • Post category:Analysis/News/Pα+
Read more about the article Breaking: Lykos Therapeutics Moved to Patent MDMA In Late 2022, Filing Reveals

Breaking: Lykos Therapeutics Moved to Patent MDMA In Late 2022, Filing Reveals

  • Post published:June 13, 2024
  • Post category:Analysis/News
Read more about the article Analysis: FDA Advisory Committee Snubs MDMA-Assisted Therapy for PTSD in Overwhelming “No” Vote

Analysis: FDA Advisory Committee Snubs MDMA-Assisted Therapy for PTSD in Overwhelming “No” Vote

  • Post published:June 11, 2024
  • Post category:Analysis/News/Pα+
Read more about the article Live Coverage: FDA Advisory Committee Reviews MDMA-Assisted Therapy for PTSD

Live Coverage: FDA Advisory Committee Reviews MDMA-Assisted Therapy for PTSD

  • Post published:June 4, 2024
  • Post category:Analysis/News

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More